Eisai R&d Management Co., Ltd.

Other

Tetsu Kawano

Toshio Imai

Yoshimasa Sakamoto

Miyuki Nishimura

Luigi Grasso

Kenzo Muramoto

Jared Spidel

Tatsuo Horizoe

James Bradford Kline

Seiichi Kobayashi

Hiroshi Shirota

Yukihisa Sawa

Brad Kline

Minghuang Zhang

The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.

Neutralizing anti-CCL20 antibodies

An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of SEQ ID NO: 91.

Anti-human XCR1 antibodies

Nucleic acids encoding neutralizing anti-CCL20 antibodies

The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.

Compositions and methods for treating inflammatory disorders

The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.

Methods of reducing the severity of mucositis

Growing community of inventors

Kobe, Japan

Tetsu Kawano